patients with chronic pain
Conditions
Interventions
Durotep MT patch 6 weeks 2.1mg~16.8mg
Sponsors
Kawasaki Medical School,Department of Orthopedics, Traumatology and Spine Surgery
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients over 20 years of age Written informed conscent to receive this therapy Visual Analog Scale of pain intensity felt in daily life of an average in patients over 40mm
Exclusion criteria
Exclusion criteria: Patients with hypersensitivity to opioids Patients with a history of opioid abuse Patients with respiratory dysfunction such as chronic lung disease Patients with asthma Patients with severe cardiac dysfunction Patients with severe liver and renal dysfunction Intracranial hypertension, patients with impaired consciousness Eczema at the site of drug patch testing, patients with atopic dermatitis, etc. Patients with fever above 40 degree was observed Pregnant women, patients might have been pregnant or nursing mothers Within two days before starting the test, patients who are scheduled to be administered to patients receiving an opioid receptor antagonist such as pentazocine or buprenorphine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS: Visual Analogue Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| SF-36 Patient satisfaction (at the end of the test is performed out of 5) Adverse event | — |
Countries
Japan
Contacts
Public ContactToru Hasegawa
Kawasaki Medical School Department of Orthopedics, Traumatology and Spine Surgery
Outcome results
None listed